Clinical trials are needed to assess the therapeutic potential of manipulating ADH to normalize the osmostat in this population with chronic hyponatremia that remains vulnerable to acute hyponatremia when water loading, driven by primary polydipsia, exceeds their water secretory capacity. The gene discussed is AVP; the disease is Hyponatremia.